COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02231710
Recruitment Status : Active, not recruiting
First Posted : September 4, 2014
Last Update Posted : January 14, 2020
Information provided by (Responsible Party):
Bellicum Pharmaceuticals

Brief Summary:
The purpose of this study is to determine a safe dose of BPX-501 gene modified T cells infused after a haplo-identical stem cell transplant to facilitate engraftment and the safety of AP1903 on day 7 to prevent GVHD.

Condition or disease Intervention/treatment Phase
Primary Immune Deficiency Disorders Hemophagocytic Lymphohistiocytosis Inherited Bone Marrow Failure Syndrome Hemoglobinopathies Metabolic Disorders Biological: BPX-501 and AP1903 Phase 1

Expanded Access : An investigational treatment associated with this study is no longer available outside the clinical trial.   More info ...

Detailed Description:
This is a single arm dose finding study evaluating the safety and efficacy of a BPX 501 infusion (T cells genetically modified with the inducible Caspase 9 suicide gene) of 3x10E6 to 1X10E7 cells/kg followed by an AP1903 infusion on day 7 after a partially mismatched, related, T cell-depleted hematopoietic cell transplantation (HCT) in patients with non-malignant diseases. The purpose of this clinical trial is to determine the dose of BPX 501 T cell infusion with subsequent planned infusion of AP1903 which can facilitate engraftment and prevent the occurrence of GVHD.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Study Evaluating BPX-501 T Cells and AP1903 for Prevention of Graft Versus Host Disease (GVHD) After Haploidentical, Related, T Cell-Depleted Hematopoietic Cell Transplantation for Non-Malignant Diseases
Study Start Date : February 2015
Actual Primary Completion Date : July 16, 2015
Estimated Study Completion Date : July 2030

Arm Intervention/treatment
Experimental: BPX-501 and AP1903
Single administration of BPX-501 T cells post partially-mismatched, related T cell depleted HCT followed by AP1903 infusion on day 7
Biological: BPX-501 and AP1903
Single administration of BPX-501 T cells post partially-mismatched, related T cell depleted HCT followed by AP1903 infusion on day 7

Primary Outcome Measures :
  1. GVHD [ Time Frame: day 100 ]
    The incidence and Grade of acute GVHD will be determined

Secondary Outcome Measures :
  1. Transplant related mortality [ Time Frame: 6 months ]
    Incidence of transplant related mortality

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   4 Months to 55 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient must meet eligibility criteria for allogeneic transplantation
  2. Males or females
  3. Age < 55 years old and > 4 months
  4. Diagnosis of a nonmalignant disorder considered treatable by HCT.
  5. Lack of suitable conventional donor

Exclusion Criteria:

  1. Serious organ dysfunction
  2. Pregnant or breast-feeding
  3. Evidence of HIV infection
  4. Bovine product allergy
  5. Patients with an active infectious disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02231710

Layout table for location information
United States, Washington
Fred Hutchinson Cancer ResearchCenter
Seattle, Washington, United States, 98109
Sponsors and Collaborators
Bellicum Pharmaceuticals
Layout table for investigator information
Principal Investigator: Lauri Burroughs, M.D. Fred Hutchinson Cancer Research Center
Layout table for additonal information
Responsible Party: Bellicum Pharmaceuticals Identifier: NCT02231710    
Other Study ID Numbers: BP-003
First Posted: September 4, 2014    Key Record Dates
Last Update Posted: January 14, 2020
Last Verified: December 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bellicum Pharmaceuticals:
Severe Combined Immune Deficiency
Congenital T-cell Defect
Congenital T-cell Deficiency
Chronic Granulomatous Disease
Shwachman Diamond Syndrome
Diamond Blackfan Anemia
Dyskeratosis Congenita
Fanconi Anemia
Sickle Cell Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphohistiocytosis, Hemophagocytic
Metabolic Diseases
Immunologic Deficiency Syndromes
Pathologic Processes
Immune System Diseases
Hematologic Diseases
Genetic Diseases, Inborn
Histiocytosis, Non-Langerhans-Cell
Lymphatic Diseases